Therapeutics

VY-AADC

Overview

Name: VY-AADC
Synonyms: VY-AADC01, VY-AADC02
Therapy Type: DNA/RNA-based
Target Type: Other Neurotransmitters (timeline)
Condition(s): Parkinson's Disease
U.S. FDA Status: Parkinson's Disease (Discontinued)
Company: Neurocrine Biosciences, Voyager Therapeutics

Background

VY-AADC is an AAV-based gene therapy developed by Voyager Therapeutics and evaluated clinically in partnership with Neurocrine Biosciences. It aims to restore the treatment benefit of oral levodopa for people with advanced Parkinson's disease whose treatment response has started fluctuating. VY-AADC attempts to supply transgenic L-amino acid decarboxylase (AADC), the enzyme that converts levodopa to dopamine, directly into the putamen area of the brain. As dopaminergic neurons in the brain's substantia nigra degenerate in PD, dopamine levels decrease in their projection area, the striatum encompassing the putamen, where medium spiny neurons survive and maintain expression of dopamine receptors long into PD progression (Braak et al., 2004). The treatment rationale is that local expression of transgenic AADC will boost dopamine levels in the putamen, reducing motor "off" time and prolonging "on" time for the patient.

VY-AADC uses the adeno-associated virus 2 capsid as a vector encoding AADC; expression is driven by a cytomegalovirus promoter. This renewed attempt at CNS gene therapy employs MRI-guided cannula placement to the putamen, convection-enhanced infusion of larger volumes of transgene solution to increase exposure, and 18F-DOPA PET to quantify local transgene expression and activity. The goal is to achieve long-term expression with a single treatment. Proof of concept, as well as safety and tolerability of this delivery mode, were reported in nonhuman primates (Su et al., 2010Hadaczek et al., 2010San Sebastian et al., 2012San Sebastian et al., 2014).

Findings

In 2013, Voyager started enrolling 15 people who had had PD for at least five years and were on levodopa therapy, into an open-label trial. It compared three ascending doses of VY-AADC, delivered once by MRI-guided neurosurgical infusion into the putamen on both sides of the brain. The primary outcome, assessed over a three-year period, was safety and tolerability; secondary outcomes included PD symptoms as recorded in participant diaries and assessed by a neurologist, as well as quality-of-life surveys, changes to Parkinson's medications, and PET scanning six months after gene transfer. Conducted at the University of California, San Francisco, and the University of Pittsburgh, the trial ended in January 2020.

Interim results were reported in December 2016, September 2017, and March 2018. Injection of up to 900 microliters of VY-AADC into the putamen was well-tolerated, distributed better throughout the putamen than previous gene therapies, and correlated with increased F-DOPA PET signal. The higher-dose cohort had higher putamen coverage, as well as dose-dependent changes in imaging, responsiveness to levodopa, and clinical measures. Thus far, the trial showed a 2.1-hour lengthening in patient-reported on-time without dyskinesia from baseline to three years for patients in Cohort 1; 3.5 hours more on-time from baseline to 18 months in Cohort 2; and 1.5 hours more up to 12 months in Cohort 3. Participants needed less oral levodopa, and VY-AADC still appeared safe at three years out. One patient had a pulmonary embolism from a venous thrombosis during the procedure, which resolved (Mar 2018 newsChristine et al., 2017). Results for all cohorts through one year post-treatment have been published (Christine et al., 2019).

In May 2017, a second open-label trial started enrolling 16 people with advanced PD who had a fluctuating levodopa response with a defined minimum of time spent in the "off" state. These participants received 9.4 x 1012 vector genomes of VY-AADC01, twice the highest dose than in the first trial, also infused once directly into the putamen. This trial evaluates delivery via an occipital, i.e. posterior, trajectory, along the long axis of the putamen, to see if that increases coverage of the putamen relative to the frontal trajectory used in the first trial. Primary outcomes include adverse events, brain abnormalities on MRI scans, routine physical exams and labs, as well as change on the Columbia-Suicide Severity Rating Scale—all recorded for up to three years after gene transfer. Secondary outcomes monitor changes in PD medications, motor function using both participant diaries and neurologist assessment, changes in dyskinesia, as well as changes in transgene expression, sleep, compulsive behavior, cognition, quality of life, and other parameters. This trial is being conducted at four U.S. sites, and is expected to run through 2021.

Preliminary results of the second open-label trial were presented at AAN in May 2019. In eight patients with advanced PD injected via the posterior route, the virus spread across half of the putamen; AADC activity, as judged by 18F-DOPA PET, increased by 85 percent. Compared with the original approach through the top of the head, time in surgery was shorter by two to three hours. A year after surgery, patients reported 1.7 hours longer on-time on levodopa, and required 28 percent less levodopa to maintain motor function than they did presurgery. Other measures of motor function and quality of life also improved. Exploratory analysis suggested that patients with high dyskinesia or impulse control disorder responded less well to the treatment (company press release; see also Nov 2019 news). According to additional data from both trials that has since been presented at meetings, improved motor function and reduced need for medication has persisted out to two and three years (Sept 2020 press release).

People from both Phase 1 studies are eligible to join an eight-year, observational follow-up safety study.

In June 2018, RESTORE-1, a Phase 2 study, began enrolling 42 people with advanced Parkinson’s disease who were responding poorly to medications. They received a single dose of VY-AADC via the occipital route, or a placebo sham surgery that involved drilling through the skull without entering the brain. Similarly to Phase 1, primary endpoints included patient rating of motor fluctuations after one year, viral coverage of putamen, change in AADC enzyme activity, and measures of safety. Secondary outcomes included change in activities of daily living, quality of life, global function, non-motor symptoms, and response to levodopa. The trial was scheduled to run to the end of 2020.

In January 2019, Voyager announced that, after consulting with the FDA, it would increase the number of patients in this trial to 75-100, and undertake a Phase 3 of similar size and design (company release) with funding from San Diego-based Neurocrine Biosciences (company release).

The company paused screening of new participants in April 2020 due to the COVID pandemic. The pause was extended in November 2020, after the safety and data monitoring board raised concerns about imaging data. A month later, the company announced that the FDA had imposed a formal clinical hold, pending more information on MRI abnormalities in trial participants (press release).

In February 2021, Neurocrine ended its agreement with Voyager regarding VY-AADC, and VY-AADC clinical development was terminated (press release, NeurologyLive).

For all VY-AADC trials, see clinicaltrials.gov.

Clinical Trial Timeline

  • Phase 1
  • Study completed / Planned end date
  • Planned end date unavailable
  • Study aborted
Sponsor Clinical Trial 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031
Voyager Therapeutics NCT01973543
N=15
Voyager Therapeutics NCT03065192
N=16

Last Updated: 24 Feb 2021

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

References

News Citations

  1. So Far, So Good for Parkinson’s Gene Therapy
  2. Time to Try Again: Gene-Based Therapy for Neurodegeneration

Paper Citations

  1. . Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson's disease. Ann Neurol. 2019 May;85(5):704-714. Epub 2019 Mar 26 PubMed.
  2. . Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004 Oct;318(1):121-34. Epub 2004 Aug 24 PubMed.
  3. . Real-time MR imaging with Gadoteridol predicts distribution of transgenes after convection-enhanced delivery of AAV2 vectors. Mol Ther. 2010 Aug;18(8):1490-5. Epub 2010 Jun 15 PubMed.
  4. . Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. Mol Ther. 2010 Aug;18(8):1458-61. Epub 2010 Jun 8 PubMed.
  5. . Safety and tolerability of magnetic resonance imaging-guided convection-enhanced delivery of AAV2-hAADC with a novel delivery platform in nonhuman primate striatum. Hum Gene Ther. 2012 Feb;23(2):210-7. Epub 2012 Jan 26 PubMed.
  6. . SAFETY AND TOLERABILITY OF MRI-GUIDED INFUSION OF AAV2-hAADC INTO THE MID-BRAIN OF NON-HUMAN PRIMATE. Mol Ther Methods Clin Dev. 2014 Oct 15;3 PubMed.

External Citations

  1. Christine et al., 2017
  2. company press release
  3. Sept 2020 press release
  4. company release
  5. company release
  6. press release
  7. press release
  8. NeurologyLive
  9. clinicaltrials.gov

Further Reading

Papers

  1. . Aromatic L-Amino Acid Decarboxylase Gene Therapy Enhances Levodopa Response in Parkinson's Disease. Mov Disord. 2020 May;35(5):851-858. Epub 2020 Mar 9 PubMed.